[
  {
    "ts": null,
    "headline": "European committee takes a second look at Alzheimer's drug and now says it should be approved",
    "summary": "A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.  Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease.  The European Commission is now expected to make a marketing authorization decision in the next few months.",
    "url": "https://finnhub.io/api/news?id=cdaf2e23afbeaa74c0cd66c33f07d1f78ab78d2c117736d7330a4dc77f0d3950",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731612030,
      "headline": "European committee takes a second look at Alzheimer's drug and now says it should be approved",
      "id": 131357762,
      "image": "https://s.yimg.com/ny/api/res/1.2/smQO.QVFqeLNNTj4rBC_ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/ap_finance_articles_694/41d9ef9c1c260a31071a7987c2de447d",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.  Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease.  The European Commission is now expected to make a marketing authorization decision in the next few months.",
      "url": "https://finnhub.io/api/news?id=cdaf2e23afbeaa74c0cd66c33f07d1f78ab78d2c117736d7330a4dc77f0d3950"
    }
  },
  {
    "ts": null,
    "headline": "5 Healthcare Stocks to Buy in a Beaten-Up Sector",
    "summary": "It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.  The  Health Care Select Sector SPDR Fund  which owns shares of major U.S. health insurers, medical device makers, and drugmakers, has dropped about 7% since hitting a record high in mid-September.  Investors have been selling healthcare stocks, buying up more economically-sensitive ones instead, as the Federal Reserve has cut interest rates and the market accounts for the positive economic consequences from Republicans winning the White House and both chambers of Congress.",
    "url": "https://finnhub.io/api/news?id=4d43b62abf62a0a77f6d4a384ab6fde494be8b5a52146c38beceb7e7075fb787",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731610380,
      "headline": "5 Healthcare Stocks to Buy in a Beaten-Up Sector",
      "id": 131357763,
      "image": "https://s.yimg.com/ny/api/res/1.2/QrvejPduXGfjO6QTtPWJsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/a741676153df2123cda83c0fb107464e",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.  The  Health Care Select Sector SPDR Fund  which owns shares of major U.S. health insurers, medical device makers, and drugmakers, has dropped about 7% since hitting a record high in mid-September.  Investors have been selling healthcare stocks, buying up more economically-sensitive ones instead, as the Federal Reserve has cut interest rates and the market accounts for the positive economic consequences from Republicans winning the White House and both chambers of Congress.",
      "url": "https://finnhub.io/api/news?id=4d43b62abf62a0a77f6d4a384ab6fde494be8b5a52146c38beceb7e7075fb787"
    }
  },
  {
    "ts": null,
    "headline": "Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment of adult patients with a clinical diagnosis of mild cognitive imp",
    "url": "https://finnhub.io/api/news?id=45fc91f78acbb7639d09d6ad18b96e66496c08b8b467c0c13957bf3be118f919",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731608940,
      "headline": "Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease",
      "id": 131357765,
      "image": "https://media.zenfs.com/en/prnewswire.com/3579c50e062a9bea3b8315d3f4b7fe57",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment of adult patients with a clinical diagnosis of mild cognitive imp",
      "url": "https://finnhub.io/api/news?id=45fc91f78acbb7639d09d6ad18b96e66496c08b8b467c0c13957bf3be118f919"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock outperforms competitors despite losses on the day",
    "summary": "Biogen Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=9ad2a27ee20767731e8b627124586d376c01110b017e2666ff7b4c18596366ea",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731603960,
      "headline": "Biogen Inc. stock outperforms competitors despite losses on the day",
      "id": 131428425,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=9ad2a27ee20767731e8b627124586d376c01110b017e2666ff7b4c18596366ea"
    }
  },
  {
    "ts": null,
    "headline": "Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal",
    "summary": "SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.",
    "url": "https://finnhub.io/api/news?id=9ff15fb98645c3acd3038c96b95ca2c77c204a7202b4c5ebce9ec59b9061a240",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731597840,
      "headline": "Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal",
      "id": 131356405,
      "image": "https://media.zenfs.com/en/zacks.com/17664ed95646b97db9beb170298a16b3",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.",
      "url": "https://finnhub.io/api/news?id=9ff15fb98645c3acd3038c96b95ca2c77c204a7202b4c5ebce9ec59b9061a240"
    }
  },
  {
    "ts": null,
    "headline": "Citi initiates coverage on 5 new biotech stocks",
    "summary": "Investing.com -- Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and Vertex (NASDAQ:VRTX).",
    "url": "https://finnhub.io/api/news?id=2f718d9f8051ba228518a6bfcb6a3d3cad58019f54abc513adba387c2f4bd164",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731596084,
      "headline": "Citi initiates coverage on 5 new biotech stocks",
      "id": 131350566,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Investing.com -- Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and Vertex (NASDAQ:VRTX).",
      "url": "https://finnhub.io/api/news?id=2f718d9f8051ba228518a6bfcb6a3d3cad58019f54abc513adba387c2f4bd164"
    }
  },
  {
    "ts": null,
    "headline": "RNA Stock Hits Record High on Entering the Cardiac Disease Space",
    "summary": "Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.",
    "url": "https://finnhub.io/api/news?id=fae4c2aabc2bce10888ccd6388b98b3b19b22bff0e0c52544909b734d09a7037",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731591360,
      "headline": "RNA Stock Hits Record High on Entering the Cardiac Disease Space",
      "id": 131350093,
      "image": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.",
      "url": "https://finnhub.io/api/news?id=fae4c2aabc2bce10888ccd6388b98b3b19b22bff0e0c52544909b734d09a7037"
    }
  },
  {
    "ts": null,
    "headline": "Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug",
    "summary": "Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug",
    "url": "https://finnhub.io/api/news?id=846aaa55906de1faa41a1e272836baf8f2af93156bfabaf1c63113402b04e3b3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731590460,
      "headline": "Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug",
      "id": 131428429,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug",
      "url": "https://finnhub.io/api/news?id=846aaa55906de1faa41a1e272836baf8f2af93156bfabaf1c63113402b04e3b3"
    }
  },
  {
    "ts": null,
    "headline": "Biogen, Eisai Win CHMP Backing of Leqembi Alzheimer's Drug",
    "summary": "By Colin Kellaher A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai. The companies on Thursday said...",
    "url": "https://finnhub.io/api/news?id=7ae519d7794c529d94e757f3e49141787711e6d281fd1e4e0c8a9ad180da5c10",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731586524,
      "headline": "Biogen, Eisai Win CHMP Backing of Leqembi Alzheimer's Drug",
      "id": 131352257,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "By Colin Kellaher A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai. The companies on Thursday said...",
      "url": "https://finnhub.io/api/news?id=7ae519d7794c529d94e757f3e49141787711e6d281fd1e4e0c8a9ad180da5c10"
    }
  },
  {
    "ts": null,
    "headline": "Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease",
    "summary": "TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 -- Eisai Co., Ltd. and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use of the...",
    "url": "https://finnhub.io/api/news?id=d88c443fe20fe4e4411228caa920ecedbd4d17049795cbc2782c554645bc18c1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731583443,
      "headline": "Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease",
      "id": 131351218,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 -- Eisai Co., Ltd. and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use of the...",
      "url": "https://finnhub.io/api/news?id=d88c443fe20fe4e4411228caa920ecedbd4d17049795cbc2782c554645bc18c1"
    }
  }
]